ABUS
Arbutus Biopharma Corp
4.90$
-3.2%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -7.1% | +55.0% | +95.7% | +46.6% | -46.1% | +345.4% | +9.2% | +2.4% | +17.0% | -39.5% | +42.9% | +55.0% | -23.6% | -13.0% | +9.0% | -3.0% | +65.8% | -94.0% | +613.3% | -44.9% | +1.9% | +15.0% | +58.9% | +255.1% | -53.5% | -66.0% | +128.2% | |
| – | – | – | +85.1% | +41.9% | +12.2% | -1.4% | -58.4% | -50.5% | +106.8% | +3.6% | +28.1% | +30.4% | -11.9% | -7.0% | +18.4% | +80.4% | +33.1% | +19.0% | +2.3% | -7.7% | -0.5% | -17.6% | -96.3% | -18.6% | +5,064.7% | -98.1% | -73.7% | |
| – | -7.1% | +55.0% | +95.7% | +46.6% | -46.1% | +345.4% | +9.2% | -44.2% | +114.7% | -122.7% | – | – | – | – | – | – | – | – | – | – | – | – | – | +255.1% | -53.5% | -66.0% | +122.3% | |
| – | -10.5% | +12.5% | +47.4% | +68.2% | +9.7% | -5.9% | -60.7% | -48.4% | +86.3% | +57.2% | +27.4% | +131,079,331.0% | -100.0% | -7.1% | +18.4% | +80.4% | +33.1% | +19.0% | +2.3% | -7.7% | -0.5% | -14.3% | +32.8% | +28.9% | -12.7% | -26.7% | -53.3% | |
| – | +17.8% | +43.9% | +37.5% | +78.1% | +22.8% | +14.3% | -51.2% | +1.8% | +15.3% | -18.5% | +9.6% | +20.5% | +29.3% | +335.0% | -79.4% | +56.9% | +203.9% | +49.0% | -59.1% | -0.6% | +10.8% | -16.3% | +15.4% | +4.1% | +26.0% | -1.6% | -28.1% | |
| – | -6.7% | +17.8% | +81.1% | +65.0% | +14.0% | -4.9% | -59.6% | -36.7% | +46.0% | -64.4% | +24.2% | +99.6% | -39.2% | -373.0% | – | +73.4% | +63.9% | +29.6% | -20.6% | -5.8% | +21.3% | -81.3% | +390.2% | +23.6% | -7.9% | -14.3% | -50.6% | |
| – | – | – | – | – | – | – | – | – | – | -514.9% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | -36.3% | -100.0% | – | -31.6% | -28.1% | -38.9% | +1,048.9% | +58.0% | -21.0% | +106.4% | -81.2% | -23.4% | +954.0% | +90.3% | -28.8% | -39.6% | -73.4% | -70.2% | -29.2% | |
| – | – | – | – | – | – | – | – | – | -114.3% | – | – | – | – | – | -147.0% | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +1,233.3% | -100.0% | – | – | – | – | -95.7% | -100.6% | – | – | -92.3% | -138.4% | – | – | -48.7% | -94.8% | -16,285.0% | – | – | – | – | – | -24.7% | +302.5% | -100.0% | – | – | |
| – | – | – | – | – | – | – | – | – | -114.3% | – | – | – | – | – | -147.0% | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | +1,501.1% | -85.5% | -336.9% | – | – | – | – | -133.8% | – | – | – | – | – | – | – | – | – | – | – | – |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.